Our Mission
SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Early detection at point of care
Nevisense
The Nevisense platform uses advanced technology powerd by AI to empower healthcare professionals by facilitating improved diagnostic accuracy, enabled disease monitoring, and early detection of melanoma at the most curable stage. Its a non-invasive measurement that provides phycisians with objective and actionable data at point-of-care.
News
Events
SciBase Partners with Skinobs to Offer Nevisense on Global Cosmetic Testing Platform
February 28, 2024STOCKHOLM, SWEDEN, - February 28, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Skinobs, a leading global platform connecting researchers with the tools they need for their cosmetic and medical research. Through this partnership, SciBase will now offer Nevisense for assessing skin barrier function within cosmetic testing on the Skinobs platform.
Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami
February 22, 2024STOCKHOLM, SWEDEN, - February 19, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders participated at the 2024 Winter Clinical Dermatology Conference in Miami. The second annual Winter Clinical Miami conference is a 4-day CME course that educates dermatologists on innovative news within Medical, and Surgical Dermatology. This prestigious CME course attracts over 400 dermatologists from the US and is considered to be one of the leading educational events for dermatology professionals.
New study shows Nevisense evaluates skin barrier function with less sensitivity to lifestyle factors than TEWL
February 16, 2024STOCKHOLM, SWEDEN, - February 16, 2024 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today the publication of the first direct comparison between electrical impedance spectroscopy (EIS) using Nevisense and trans-epidermal water loss (TEWL). The study demonstrates Nevisense as a more robust technique to assess skin barrier function than the commonly accepted TEWL measurement technique.
SciBase initiates collaboration with Inderes for commissioned research
January 30, 2024STOCKHOLM, SWEDEN, - January 30, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology initiates cooperation with Inderes (www.inderes.se) for ongoing services related to commissioned research. This collaboration aims at providing high-quality equity research on SciBase Holding AB stock.
Reminder: Welcome to SciBase Capital Markets Day 2024
January 19, 2024STOCKHOLM, SWEDEN, - January 19, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day on January 25, 2024.
Welcome to SciBase Capital Markets Day 2024
January 9, 2024STOCKHOLM, SWEDEN, - January 25, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024.
- Load more news...
News
Our unique platform
Nevisense
The unique Nevisense platform utilizes advanced EIS- technology combined with AI to empower healthcare professionals by improving diagnostic accuracy, enabling disease monitoring, and facilitating early detection of skin cancer. The Nevisense procedure is non-invasive and provides clinicians with objective and actionable data, at point-of-care. It has been developed based on 20+ years of research from the Karolinska Institute and several years of clinical experience.
Lorem ipsum dolor
Lorem ipsum dolor
Integer venenatis sem in orci volutpat, eget placerat est mattis. Vivamus rhoncus leo sed nulla aliquam, id suscipit libero sagittis. Aenean vitae condimentum nisi, ac hendrerit libero.